Bivariate Analysis of the Severity and Duration of Influenzalike Illness Symptoms Among Subjects With Cell Culture–Confirmed Influenza Infection
| No. (%) of Subjects With Symptoms | |||||||
| Symptoms | Total | Mild | Moderate | Severe | Mean Severity Scorea | Duration, Days, Mean (Median) | P Valueb |
| VCIV (n = 21) | |||||||
| Pyrexia | 12 (57) | 5 (23.8) | 6 (28.6) | 1 (4.8) | 1.7 | 3.6 (3.0) | .491 |
| Cough | 15 (71) | 9 (42.9) | 6 (28.6) | 0 | 1.4 | 8.8 (7.0) | .143 |
| Oropharyngeal pain | 16 (76) | 10 (47.6) | 6 (28.6) | 0 | 1.4 | 7.4 (5.0) | .083 |
| Myalgia | 13 (62) | 8 (38.1) | 5 (23.8) | 0 | 1.4 | 4.2 (3.0) | .003 |
| Headache | 11 (52) | 9 (42.9) | 2 (9.5) | 0 | 1.2 | 5.6 (5.0) | .025 |
| Fatigue | 12 (57) | 8 (38.1) | 3 (14.3) | 1 (4.8) | 1.4 | 4.9 (3.5) | .013 |
| Nausea | 8 (38) | 5 (23.8) | 3 (14.3) | 0 | 1.4 | 6.9 (6.0) | .479 |
| Placebo (n = 74) | |||||||
| Pyrexia | 48 (65) | 26 (35.1) | 17 (23.0) | 5 (6.8) | 1.6 | 4.4 (3.5) | … |
| Cough | 63 (85) | 28 (37.8) | 30 (40.5) | 5 (6.8) | 1.6 | 10.0 (8.0) | … |
| Oropharyngeal pain | 43 (58) | 21 (28.4) | 19 (25.7) | 3 (4.1) | 1.6 | 8.1 (7.0) | … |
| Myalgia | 51 (69) | 20 (27.0) | 29 (39.2) | 2 (2.7) | 1.6 | 7.8 (7.0) | … |
| Headache | 45 (61) | 24 (32.4) | 17 (23.0) | 4 (5.4) | 1.6 | 7.1 (6.0) | … |
| Fatigue | 42 (57) | 19 (25.7) | 21 (28.4) | 2 (2.7) | 1.6 | 7.4 (6.0) | … |
| Nausea | 21 (28) | 11 (14.9) | 10 (13.5) | 0 | 1.5 | 5.1 (5.0) | … |
| No. (%) of Subjects With Symptoms | |||||||
| Symptoms | Total | Mild | Moderate | Severe | Mean Severity Scorea | Duration, Days, Mean (Median) | P Valueb |
| VCIV (n = 21) | |||||||
| Pyrexia | 12 (57) | 5 (23.8) | 6 (28.6) | 1 (4.8) | 1.7 | 3.6 (3.0) | .491 |
| Cough | 15 (71) | 9 (42.9) | 6 (28.6) | 0 | 1.4 | 8.8 (7.0) | .143 |
| Oropharyngeal pain | 16 (76) | 10 (47.6) | 6 (28.6) | 0 | 1.4 | 7.4 (5.0) | .083 |
| Myalgia | 13 (62) | 8 (38.1) | 5 (23.8) | 0 | 1.4 | 4.2 (3.0) | .003 |
| Headache | 11 (52) | 9 (42.9) | 2 (9.5) | 0 | 1.2 | 5.6 (5.0) | .025 |
| Fatigue | 12 (57) | 8 (38.1) | 3 (14.3) | 1 (4.8) | 1.4 | 4.9 (3.5) | .013 |
| Nausea | 8 (38) | 5 (23.8) | 3 (14.3) | 0 | 1.4 | 6.9 (6.0) | .479 |
| Placebo (n = 74) | |||||||
| Pyrexia | 48 (65) | 26 (35.1) | 17 (23.0) | 5 (6.8) | 1.6 | 4.4 (3.5) | … |
| Cough | 63 (85) | 28 (37.8) | 30 (40.5) | 5 (6.8) | 1.6 | 10.0 (8.0) | … |
| Oropharyngeal pain | 43 (58) | 21 (28.4) | 19 (25.7) | 3 (4.1) | 1.6 | 8.1 (7.0) | … |
| Myalgia | 51 (69) | 20 (27.0) | 29 (39.2) | 2 (2.7) | 1.6 | 7.8 (7.0) | … |
| Headache | 45 (61) | 24 (32.4) | 17 (23.0) | 4 (5.4) | 1.6 | 7.1 (6.0) | … |
| Fatigue | 42 (57) | 19 (25.7) | 21 (28.4) | 2 (2.7) | 1.6 | 7.4 (6.0) | … |
| Nausea | 21 (28) | 11 (14.9) | 10 (13.5) | 0 | 1.5 | 5.1 (5.0) | … |
Abbreviations: ILI, influenzalike illness; VCIV, Vero cell culture–derived influenza vaccine.
Symptoms rated as mild were given a score of 1, moderate symptoms a score of 2, and severe symptoms a score of 3.
P value (POSET test) of the reduction in severity and duration of symptoms in VCIV recipients compared with placebo recipients.
Bivariate Analysis of the Severity and Duration of Influenzalike Illness Symptoms Among Subjects With Cell Culture–Confirmed Influenza Infection
| No. (%) of Subjects With Symptoms | |||||||
| Symptoms | Total | Mild | Moderate | Severe | Mean Severity Scorea | Duration, Days, Mean (Median) | P Valueb |
| VCIV (n = 21) | |||||||
| Pyrexia | 12 (57) | 5 (23.8) | 6 (28.6) | 1 (4.8) | 1.7 | 3.6 (3.0) | .491 |
| Cough | 15 (71) | 9 (42.9) | 6 (28.6) | 0 | 1.4 | 8.8 (7.0) | .143 |
| Oropharyngeal pain | 16 (76) | 10 (47.6) | 6 (28.6) | 0 | 1.4 | 7.4 (5.0) | .083 |
| Myalgia | 13 (62) | 8 (38.1) | 5 (23.8) | 0 | 1.4 | 4.2 (3.0) | .003 |
| Headache | 11 (52) | 9 (42.9) | 2 (9.5) | 0 | 1.2 | 5.6 (5.0) | .025 |
| Fatigue | 12 (57) | 8 (38.1) | 3 (14.3) | 1 (4.8) | 1.4 | 4.9 (3.5) | .013 |
| Nausea | 8 (38) | 5 (23.8) | 3 (14.3) | 0 | 1.4 | 6.9 (6.0) | .479 |
| Placebo (n = 74) | |||||||
| Pyrexia | 48 (65) | 26 (35.1) | 17 (23.0) | 5 (6.8) | 1.6 | 4.4 (3.5) | … |
| Cough | 63 (85) | 28 (37.8) | 30 (40.5) | 5 (6.8) | 1.6 | 10.0 (8.0) | … |
| Oropharyngeal pain | 43 (58) | 21 (28.4) | 19 (25.7) | 3 (4.1) | 1.6 | 8.1 (7.0) | … |
| Myalgia | 51 (69) | 20 (27.0) | 29 (39.2) | 2 (2.7) | 1.6 | 7.8 (7.0) | … |
| Headache | 45 (61) | 24 (32.4) | 17 (23.0) | 4 (5.4) | 1.6 | 7.1 (6.0) | … |
| Fatigue | 42 (57) | 19 (25.7) | 21 (28.4) | 2 (2.7) | 1.6 | 7.4 (6.0) | … |
| Nausea | 21 (28) | 11 (14.9) | 10 (13.5) | 0 | 1.5 | 5.1 (5.0) | … |
| No. (%) of Subjects With Symptoms | |||||||
| Symptoms | Total | Mild | Moderate | Severe | Mean Severity Scorea | Duration, Days, Mean (Median) | P Valueb |
| VCIV (n = 21) | |||||||
| Pyrexia | 12 (57) | 5 (23.8) | 6 (28.6) | 1 (4.8) | 1.7 | 3.6 (3.0) | .491 |
| Cough | 15 (71) | 9 (42.9) | 6 (28.6) | 0 | 1.4 | 8.8 (7.0) | .143 |
| Oropharyngeal pain | 16 (76) | 10 (47.6) | 6 (28.6) | 0 | 1.4 | 7.4 (5.0) | .083 |
| Myalgia | 13 (62) | 8 (38.1) | 5 (23.8) | 0 | 1.4 | 4.2 (3.0) | .003 |
| Headache | 11 (52) | 9 (42.9) | 2 (9.5) | 0 | 1.2 | 5.6 (5.0) | .025 |
| Fatigue | 12 (57) | 8 (38.1) | 3 (14.3) | 1 (4.8) | 1.4 | 4.9 (3.5) | .013 |
| Nausea | 8 (38) | 5 (23.8) | 3 (14.3) | 0 | 1.4 | 6.9 (6.0) | .479 |
| Placebo (n = 74) | |||||||
| Pyrexia | 48 (65) | 26 (35.1) | 17 (23.0) | 5 (6.8) | 1.6 | 4.4 (3.5) | … |
| Cough | 63 (85) | 28 (37.8) | 30 (40.5) | 5 (6.8) | 1.6 | 10.0 (8.0) | … |
| Oropharyngeal pain | 43 (58) | 21 (28.4) | 19 (25.7) | 3 (4.1) | 1.6 | 8.1 (7.0) | … |
| Myalgia | 51 (69) | 20 (27.0) | 29 (39.2) | 2 (2.7) | 1.6 | 7.8 (7.0) | … |
| Headache | 45 (61) | 24 (32.4) | 17 (23.0) | 4 (5.4) | 1.6 | 7.1 (6.0) | … |
| Fatigue | 42 (57) | 19 (25.7) | 21 (28.4) | 2 (2.7) | 1.6 | 7.4 (6.0) | … |
| Nausea | 21 (28) | 11 (14.9) | 10 (13.5) | 0 | 1.5 | 5.1 (5.0) | … |
Abbreviations: ILI, influenzalike illness; VCIV, Vero cell culture–derived influenza vaccine.
Symptoms rated as mild were given a score of 1, moderate symptoms a score of 2, and severe symptoms a score of 3.
P value (POSET test) of the reduction in severity and duration of symptoms in VCIV recipients compared with placebo recipients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
